Temperaturesensitive live-attenuated canine influenza virus H3N8 vaccine

Journal of Virology

Volumn 91, Issue 4, 2017, Pages

  Nogales, Aitor ^a   Rodriguez, Laura ^a   Chauché, Caroline ^b   Huang, Kai ^c   Reilly, Emma C ^a   Topham, David J ^a   Murcia, Pablo R ^b   Parrish, Colin R ^c   Martínez Sobrido, Luis ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b MRC UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH   (United Kingdom)

^c Cornell University ^*  (United States)

Author keywords

Influenza; Influenza vaccines

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; KENNEL COUGH VACCINE; LIVE VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; DRUG SAFETY; EX VIVO STUDY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VIVO STUDY; INFLUENZA A (H3N2); INFLUENZA A (H3N8); INFLUENZA A VIRUS (H3N8); MOUSE; NONHUMAN; SINGLE DRUG DOSE; VIRUS REPLICATION; VIRUS TITRATION; ANIMAL; CELL LINE; DOG; DOG DISEASES; GENETICS; IMMUNIZATION; IMMUNOLOGY; INFLUENZA A VIRUS (H3N2); MUTATION; ORTHOMYXOVIRUS INFECTION; VETERINARY;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELL LINE; CROSS REACTIONS; DOG DISEASES; DOGS; FEMALE; IMMUNIZATION; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H3N8 SUBTYPE; INFLUENZA VACCINES; MICE; MUTATION; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, ATTENUATED;

EID: 85011973250     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02211-16     Document Type: Article

References (76)

1. Baker SF, Nogales A, Martinez-Sobrido L. 2015. Downregulating viral gene expression: codon usage bias manipulation for the generation of novel influenza A virus vaccines. Future Virol 10:715-730. https://doi.org/10.2217/fvl.15.31.
2. Varghese JN, McKimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM. 1992. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14:327-332. https://doi.org/10.1002/prot.340140302.
3. Carrat F, Flahault A. 2007. Influenza vaccine: the challenge of antigenic drift. Vaccine 25:6852-6862. https://doi.org/10.1016/j.vaccine.2007.07.027.
4. Palese PS, ML. 2007. Orthomyxoviridae: the viruses and their replication, p 1647-1690. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA (ed), Fields virology, 5th ed. Lippincott/Williams & Wilkins, Philadelphia, PA.
5. Tong S, Zhu X, Li Y, Shi M, Zhang J, Bourgeois M, Yang H, Chen X, Recuenco S, Gomez J, Chen LM, Johnson A, Tao Y, Dreyfus C, Yu W, McBride R, Carney PJ, Gilbert AT, Chang J, Guo Z, Davis CT, Paulson JC, Stevens J, Rupprecht CE, Holmes EC, Wilson IA, Donis RO. 2013. New world bats harbor diverse influenza A viruses. PLoS Pathog 9:e1003657. https://doi.org/10.1371/journal.ppat.1003657.
6. de Jong JC, Smith DJ, Lapedes AS, Donatelli I, Campitelli L, Barigazzi G, Van Reeth K, Jones TC, Rimmelzwaan GF, Osterhaus AD, Fouchier RA. 2007. Antigenic and genetic evolution of swine influenza A (H3N2) viruses in Europe. J Virol 81:4315-4322. https://doi.org/10.1128/JVI.02458-06.
7. Taubenberger JK, Kash JC. 2010. Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe 7:440-451. https://doi.org/10.1016/j.chom.2010.05.009.
8. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. 1992. Evolution and ecology of influenza A viruses. Microbiol Rev 56:152-179.
9. Yoon SW, Webby RJ, Webster RG. 2014. Evolution and ecology of influenza a viruses. Curr Top Microbiol Immunol 385:359-375.
10. Crawford PC, Dubovi EJ, Castleman WL, Stephenson I, Gibbs EP, Chen L, Smith C, Hill RC, Ferro P, Pompey J, Bright RA, Medina MJ, Johnson CM, Olsen CW, Cox NJ, Klimov AI, Katz JM, Donis RO. 2005. Transmission of equine influenza virus to dogs. Science 310:482-485. https://doi.org/10.1126/science.1117950.
11. Song D, Kang B, Lee C, Jung K, Ha G, Kang D, Park S, Park B, Oh J. 2008. Transmission of avian influenza virus (H3N2) to dogs. Emerg Infect Dis 14:741-746. https://doi.org/10.3201/eid1405.071471.
12. JAVMA News. 2015. Outbreak of canine influenza caused by new strain of virus. J Am Vet Med Assoc 246:1049.
13. Jeoung HY, Lim SI, Shin BH, Lim JA, Song JY, Song DS, Kang BK, Moon HJ, An DJ. 2013. A novel canine influenza H3N2 virus isolated from cats in an animal shelter. Vet Microbiol 165:281-286. https://doi.org/10.1016/j.vetmic.2013.03.021.
14. Song DS, An DJ, Moon HJ, Yeom MJ, Jeong HY, Jeong WS, Park SJ, Kim HK, Han SY, Oh J S, Park BK, Kim JK, Poo H, Webster RG, Jung K, Kang BK. 2011. Interspecies transmission of the canine influenza H3N2 virus to domestic cats in South Korea. J Gen Virol 92:2350-2355. https://doi.org/10.1099/vir.0.033522-0.
15. Yoon KJ, Cooper VL, Schwartz KJ, Harmon KM, Kim WI, Janke BH, Strohbehn J, Butts D, Troutman J. 2005. Influenza virus infection in racing greyhounds. Emerg Infect Dis 11:1974-1976. https://doi.org/10.3201/eid1112.050810.
16. Holt DE, Mover MR, Brown DC. 2010. Serologic prevalence of antibodies against canine influenza virus (H3N8) in dogs in a metropolitan animal shelter. J Am Vet Med Assoc 237:71-73. https://doi.org/10.2460/javma.237.1.71.
17. Pecoraro HL, Spindel ME, Bennett S, Lunn KF, Landolt GA. 2013. Evaluation of virus isolation, one-step real-time reverse transcription polymerase chain reaction assay, and two rapid influenza diagnostic tests for detecting canine Influenza A virus H3N8 shedding in dogs. J Vet Diagn Invest 25:402-406. https://doi.org/10.1177/1040638713480500.
18. Gonzalez G, Marshall JF, Morrell J, Robb D, McCauley JW, Perez DR, Parrish CR, Murcia PR. 2014. Infection and pathogenesis of canine, equine, and human influenza viruses in canine tracheas. J Virol 88: 9208-9219. https://doi.org/10.1128/JVI.00887-14.
19. Song D, Kim H, Na W, Hong M, Park SJ, Moon H, Kang B, Lyoo KS, Yeom M, Jeong DG, An DJ, Kim JK. 2015. Canine susceptibility to human influenza viruses (A/pdm 09H1N1, A/H3N2 and B). J Gen Virol 96: 254-258. https://doi.org/10.1099/vir.0.070821-0.
20. Song D, Moon HJ, An DJ, Jeoung HY, Kim H, Yeom MJ, Hong M, Nam JH, Park SJ, Park BK, Oh J S, Song M, Webster RG, Kim JK, Kang BK. 2012. A novel reassortant canine H3N1 influenza virus between pandemic H1N1 and canine H3N2 influenza viruses in Korea. J Gen Virol 93:551-554. https://doi.org/10.1099/vir.0.037739-0.
21. Yen HL, Webster RG. 2009. Pandemic influenza as a current threat. Curr Top Microbiol Immunol 333:3-24.
22. Pica N, Palese P. 2013. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med 64:189-202. https://doi.org/10.1146/annurev-med-120611-145115.
23. Wong SS, Webby RJ. 2013. Traditional and new influenza vaccines. Clin Microbiol Rev 26:476-492. https://doi.org/10.1128/CMR.00097-12.
24. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM, CAIV-T Comparative Efficacy Study Group. 2007. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356:685-696. https://doi.org/10.1056/NEJMoa065368.
25. Cox MM, Patriarca PA, Treanor J. 2008. FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respir Viruses 2:211-219. https://doi.org/10.1111/j.1750-2659.2008.00053.x.
26. Osterholm MT, Kelley NS, Sommer A, Belongia EA. 2012. Efficacy and effectiveness of influenza vaccines: a systematic review and metaanalysis. Lancet Infect Dis 12:36-44. https://doi.org/10.1016/S1473-3099(11)70295-X.
27. Pronker ES, Claassen E, Osterhaus AD. 2012. Development of new generation influenza vaccines: recipes for success? Vaccine 30:7344-7347. https://doi.org/10.1016/j.vaccine.2012.09.071.
28. Nogales A, Huang K, Chauche C, DeDiego ML, Murcia PR, Parrish CR, Martinez-Sobrido L. 2017. Canine influenza viruses with modified NS1 proteins for the development of live-attenuated vaccines. Virology 500: 1-10. https://doi.org/10.1016/j.virol.2016.10.008.
29. Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, Lindstrom S, Shay DK. 2009. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 199:159-167. https://doi.org/10.1086/595861.
30. Gorse GJ, Belshe RB, Munn NJ. 1991. Superiority of live attenuated compared with inactivated influenza A virus vaccines in older, chronically ill adults. Chest 100:977-984. https://doi.org/10.1378/chest.100.4.977.
31. Maassab HF. 1968. Plaque formation of influenza virus at 25°C. Nature 219:645-646.
32. Chan W, Zhou H, Kemble G, Jin H. 2008. The cold adapted and temperature sensitive influenza A/Ann Arbor/6/60 virus, the master donor virus for live attenuated influenza vaccines, has multiple defects in replication at the restrictive temperature. Virology 380:304-311. https://doi.org/10.1016/j.virol.2008.07.027.
33. Cox NJ, Kitame F, Kendal AP, Maassab HF, Naeve C. 1988. Identification of sequence changes in the cold-adapted, live attenuated influenza vaccine strain, A/Ann Arbor/6/60 (H2N2). Virology 167:554-567. https://doi.org/10.1016/S0042-6822(88)90118-3.
34. Snyder MH, Betts RF, DeBorde D, Tierney EL, Clements ML, Herrington D, Sears SD, Dolin R, Maassab HF, Murphy BR. 1988. Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J Virol 62:488-495.
35. Cox A, Baker SF, Nogales A, Martinez-Sobrido L, Dewhurst S. 2015. Development of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine. J Virol 89:3421-3426. https://doi.org/10.1128/JVI.02636-14.
36. Jin H, Zhou H, Lu B, Kemble G. 2004. Imparting temperature sensitivity and attenuation in ferrets to A/Puerto Rico/8/34 influenza virus by transferring the genetic signature for temperature sensitivity from coldadapted A/Ann Arbor/6/60. J Virol 78:995-998. https://doi.org/10.1128/JVI.78.2.995-998.2004.
37. Zhou B, Li Y, Speer SD, Subba A, Lin X, Wentworth DE. 2012. Engineering temperature-sensitive live attenuated influenza vaccines from emerging viruses. Vaccine 30:3691-3702. https://doi.org/10.1016/j.vaccine.2012.03.025.
38. Martinez-Sobrido L, Garcia-Sastre A. 2010. Generation of recombinant influenza virus from plasmid DNA. J Vis Exp 2010:2057. https://doi.org/10.3791/2057.
39. Jin H, Lu B, Zhou H, Ma C, Zhao J, Yang CF, Kemble G, Greenberg H. 2003. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 306:18-24. https://doi.org/10.1016/S0042-6822(02)00035-1.
40. Nogales A, Baker SF, Ortiz-Riano E, Dewhurst S, Topham DJ, Martinez-Sobrido L. 2014. Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development. J Virol 88:10525-10540. https://doi.org/10.1128/JVI.01565-14.
41. Nogales A, DeDiego ML, Topham DJ, Martinez-Sobrido L. 2016. Rearrangement of influenza virus spliced segments for the development of live-attenuated vaccines. J Virol 90:6291-6302. https://doi.org/10.1128/JVI.00410-16.
42. Baker SF, Guo H, Albrecht RA, Garcia-Sastre A, Topham DJ, Martinez-Sobrido L. 2013. Protection against lethal influenza with a viral mimic. J Virol 87:8591-8605. https://doi.org/10.1128/JVI.01081-13.
43. Reilly EC, Lambert-Emo K, Topham DJ. 2016. The effects of acute neutrophil depletion on resolution of acute influenza infection, establishment of tissue resident memory (TRM), and heterosubtypic immunity. PLoS One 11:e0164247. https://doi.org/10.1371/journal.pone.0164247.
44. Maassab HF, Bryant ML. 1999. The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev Med Virol 9:237-244. https://doi.org/10.1002/(SICI)1099-1654(199910/12)9:4<237::AID-RMV252>3.0.CO;2-G.
45. Murphy BR, Coelingh K. 2002. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 15:295-323. https://doi.org/10.1089/08828240260066242.
46. Cox A, Baker SF, Nogales A, Martinez-Sobrido L, Dewhurst S. 2014. Development of a mouse-adapted, live-attenuated influenza virus that permits in vivo analysis of enhancements to the safety of LAIV. J Virol 89:3421-3426. https://doi.org/10.1128/JVI.02636-14.
47. Kohlmeier JE, Woodland DL. 2009. Immunity to respiratory viruses. Annu Rev Immunol 27:61-82. https://doi.org/10.1146/annurev.immunol.021908.132625.
48. Cheng X, Zengel JR, Suguitan AL, Jr, Xu Q, Wang W, Lin J, Jin H. 2013. Evaluation of the humoral and cellular immune responses elicited by the live attenuated and inactivated influenza vaccines and their roles in heterologous protection in ferrets. J Infect Dis 208:594-602. https://doi.org/10.1093/infdis/jit207.
49. De Villiers PJ, Steele AD, Hiemstra LA, Rappaport R, Dunning AJ, Gruber WC, Forrest BD. 2009. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine 28:228-234. https://doi.org/10.1016/j.vaccine.2009.09.092.
50. Katsura H, Iwatsuki-Horimoto K, Fukuyama S, Watanabe S, Sakabe S, Hatta Y, Murakami S, Shimojima M, Horimoto T, Kawaoka Y. 2012. A replication-incompetent virus possessing an uncleavable hemagglutinin as an influenza vaccine. Vaccine 30:6027-6033. https://doi.org/10.1016/j.vaccine.2012.07.059.
51. Victor ST, Watanabe S, Katsura H, Ozawa M, Kawaoka Y. 2012. A replication-incompetent PB2-knockout influenza A virus vaccine vector. J Virol 89:3421-3426. https://doi.org/10.1128/JVI.02636-14.
52. Guo H, Baker SF, Martinez-Sobrido L, Topham DJ. 2014. Induction of CD8 T cell heterologous protection by a single dose of single-cycle infectious influenza virus. J Virol 88:12006-12016. https://doi.org/10.1128/JVI.01847-14.
53. Powell TJ, Silk JD, Sharps J, Fodor E, Townsend AR. 2012. Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity. J Virol 86:13397-13406. https://doi.org/10.1128/JVI.01820-12.
54. Uraki R, Kiso M, Iwatsuki-Horimoto K, Fukuyama S, Takashita E, Ozawa M, Kawaoka Y. 2013. A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges. J Virol 87:7874-7881. https://doi.org/10.1128/JVI.00076-13.
55. Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, Abate G, Sakala IG, Edwards KM, Creech CB, Gerber MA, Bernstein DI, Newman F, Graham I, Anderson EL, Belshe RB. 2011. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 204:845-853. https://doi.org/10.1093/infdis/jir436.
56. Hayward JJ, Dubovi EJ, Scarlett JM, Janeczko S, Holmes EC, Parrish CR. 2010. Microevolution of canine influenza virus in shelters and its molecular epidemiology in the United States. J Virol 84:12636-12645. https://doi.org/10.1128/JVI.01350-10.
57. Rivailler P, Perry IA, Jang Y, Davis CT, Chen LM, Dubovi EJ, Donis RO. 2010. Evolution of canine and equine influenza (H3N8) viruses cocirculating between 2005 and 2008. Virology 408:71-79. https://doi.org/10.1016/j.virol.2010.08.022.
58. Bean WJ, Schell M, Katz J, Kawaoka Y, Naeve C, Gorman O, Webster RG. 1992. Evolution of the H3 influenza virus hemagglutinin from human and nonhuman hosts. J Virol 66:1129-1138.
59. Both GW, Sleigh MJ, Cox NJ, Kendal AP. 1983. Antigenic drift in influenza virus H3 hemagglutinin from 1968 to 1980: multiple evolutionary pathways and sequential amino acid changes at key antigenic sites. J Virol 48:52-60.
60. Bush RM, Fitch WM, Bender CA, Cox NJ. 1999. Positive selection on the H3 hemagglutinin gene of human influenza virus A. Mol Biol Evol 16:1457-1465. https://doi.org/10.1093/oxfordjournals.molbev.a026057.
61. Epperson S, Jhung M, Richards S, Quinlisk P, Ball L, Moll M, Boulton R, Haddy L, Biggerstaff M, Brammer L, Trock S, Burns E, Gomez T, Wong KK, Katz J, Lindstrom S, Klimov A, Bresee JS, Jernigan DB, Cox N, Finelli L. 2013. Human infections with influenza A(H3N2) variant virus in the United States, 2011-2012. Clin Infect Dis 57(Suppl 1):S4-S11. https://doi.org/10.1093/cid/cit272.
62. Larson LJ, Henningson J, Sharp P, Thiel B, Deshpande MS, Davis T, Jayappa H, Wasmoen T, Lakshmanan N, Schultz RD. 2011. Efficacy of the canine influenza virus H3N8 vaccine to decrease severity of clinical disease after cochallenge with canine influenza virus and Streptococcus equi subsp. zooepidemicus. Clin Vaccine Immunol 18:559-564. https://doi.org/10.1128/CVI.00500-10.
63. Hale BG, Randall RE, Ortin J, Jackson D. 2008. The multifunctional NS1 protein of influenza A viruses. J Gen Virol 89:2359-2376. https://doi.org/10.1099/vir.0.2008/004606-0.
64. Baskin CR, Bielefeldt-Ohmann H, Garcia-Sastre A, Tumpey TM, Van Hoeven N, Carter VS, Thomas MJ, Proll S, Solorzano A, Billharz R, Fornek JL, Thomas S, Chen CH, Clark EA, Murali-Krishna K, Katze MG. 2007. Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus. J Virol 81:11817-11827. https://doi.org/10.1128/JVI.00590-07.
65. Choi EH, Song MS, Park SJ, Pascua PN, Baek YH, Kwon HI, Kim EH, Kim S, Jang HK, Poo H, Kim CJ, Choi YK. 2015. Development of a dual-protective live attenuated vaccine against H5N1 and H9N2 avian influenza viruses by modifying the NS1 gene. Arch Virol 160:1729-1740. https://doi.org/10.1007/s00705-015-2442-y.
66. Pica N, Langlois RA, Krammer F, Margine I, Palese P. 2012. NS1-truncated live attenuated virus vaccine provides robust protection to aged mice from viral challenge. J Virol 86:10293-10301. https://doi.org/10.1128/JVI.01131-12.
67. Quinlivan M, Zamarin D, Garcia-Sastre A, Cullinane A, Chambers T, Palese P. 2005. Attenuation of equine influenza viruses through truncations of the NS1 protein. J Virol 79:8431-8439. https://doi.org/10.1128/JVI.79.13.8431-8439.2005.
68. Richt JA, Lekcharoensuk P, Lager KM, Vincent AL, Loiacono CM, Janke BH, Wu WH, Yoon KJ, Webby RJ, Solorzano A, Garcia-Sastre A. 2006. Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine. J Virol 80:11009-11018. https://doi.org/10.1128/JVI.00787-06.
69. Solorzano A, Webby RJ, Lager KM, Janke BH, Garcia-Sastre A, Richt JA. 2005. Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J Virol 79: 7535-7543. https://doi.org/10.1128/JVI.79.12.7535-7543.2005.
70. Steel J, Lowen AC, Pena L, Angel M, Solorzano A, Albrecht R, Perez DR, Garcia-Sastre A, Palese P. 2009. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol 83:1742-1753. https://doi.org/10.1128/JVI.01920-08.
71. Vincent AL, Ma W, Lager KM, Janke BH, Webby RJ, Garcia-Sastre A, Richt JA. 2007. Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine 25:7999-8009. https://doi.org/10.1016/j.vaccine.2007.09.019.
72. Feng KH, Gonzalez G, Deng L, Yu H, Tse VL, Huang L, Huang K, Wasik BR, Zhou B, Wentworth DE, Holmes EC, Chen X, Varki A, Murcia PR, Parrish CR. 2015. Equine and canine influenza H3N8 viruses show minimal biological differences despite phylogenetic divergence. J Virol 89: 6860-6873. https://doi.org/10.1128/JVI.00521-15.
73. Murakami S, Horimoto T, Yamada S, Kakugawa S, Goto H, Kawaoka Y. 2008. Establishment of canine RNA polymerase I-driven reverse genetics for influenza A virus: its application for H5N1 vaccine production. J Virol 82:1605-1609. https://doi.org/10.1128/JVI.01876-07.
74. Cheng BY, Ortiz-Riano E, Nogales A, de la Torre JC, Martinez-Sobrido L. 2015. Development of live-attenuated arenavirus vaccines based on codon deoptimization. J Virol 89:3523-3533. https://doi.org/10.1128/JVI.03401-14.
75. Nogales A, Baker SF, Martinez-Sobrido L. 2014. Replication-competent influenza A viruses expressing a red fluorescent protein. Virology 476C: 206-216.
76. National Research Council, Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research, and National Academies Press. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.